Bolt Biotherapeutics (NASDAQ:BOLT) Issues Earnings Results

Posted by on Apr 1st, 2021 // Comments off

Bolt Biotherapeutics (NASDAQ:BOLT) issued its quarterly earnings data on Tuesday. The company reported ($14.58) EPS for the quarter, missing analysts’ consensus estimates of ($1.80) by ($12.78), Fidelity Earnings reports.

Shares of BOLT traded down $3.22 during midday trading on Thursday, hitting $29.69. The company had a trading volume of 5,301 shares, compared to its average volume of 352,864. The firm has a 50 day moving average price of $32.48. Bolt Biotherapeutics has a 52 week low of $22.63 and a 52 week high of $43.07.

In other Bolt Biotherapeutics news, major shareholder Vivo Capital Fund Viii, L.P. acquired 350,000 shares of the stock in a transaction that occurred on Tuesday, February 9th. The stock was acquired at an average price of $20.00 per share, with a total value of $7,000,000.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Randall C. Schatzman acquired 1,500 shares of the stock in a transaction that occurred on Tuesday, February 9th. The shares were acquired at an average cost of $20.00 per share, with a total value of $30,000.00. Insiders bought a total of 552,700 shares of company stock valued at $11,054,000 in the last three months.

BOLT has been the topic of a number of recent analyst reports. Stifel Nicolaus initiated coverage on shares of Bolt Biotherapeutics in a report on Monday, March 8th. They issued a “buy” rating and a $40.00 price objective on the stock. Guggenheim initiated coverage on shares of Bolt Biotherapeutics in a report on Monday, March 8th. They issued a “buy” rating and a $42.00 price objective on the stock. Morgan Stanley initiated coverage on shares of Bolt Biotherapeutics in a report on Monday, March 8th. They issued an “overweight” rating and a $45.00 price objective on the stock. Finally, SVB Leerink began coverage on shares of Bolt Biotherapeutics in a report on Monday, March 8th. They issued an “outperform” rating and a $36.00 price objective on the stock.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage immuno-oncology company, engages in the discovery, development, and commercialization of pharmaceutical products. The company develops BDC-1001, a human epidermal growth factor receptor 2 (HER2) for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors.

Featured Story: Should You Consider an Index Fund?

Receive News & Ratings for Bolt Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bolt Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.